Materials · Specialty Chemicals · US stock · price as of 22 Oct 2026
Key indicators
Price
$92.54
52-week range
$88.01 – $221.00
Market cap
$12.6B
P/E (trailing)
50.6×
EV / EBITDA
14.4×
Free-cash-flow yield
10.6%
Dividend yield
1.8%
Revenue (last 12 months)
$5.9B
Revenue growth (3y a year)
−11.1%
Operating margin
4.3%
Return on invested capital
1.7%
Net debt / EBITDA
0.4×
Fair value
Fair value (average of valid models)$97.12 middle half of models $90 – $111
Versus priceFair+5% to fair value
P/E multiple
$86.80
P/B multiple
$137.87
P/S multiple
$111.95
EV/EBITDA multiple
$110.43
EV/EBIT multiple
$65.75
EV/revenue multiple
$111.16
10-year DCF, EBITDA exit
$90.99
5-year DCF, EBITDA exit
$98.49
10-year DCF, revenue exit
$91.36
5-year DCF, revenue exit
$97.70
Dividend discount, stable
$62.52
Dividend discount, multi-stage
$100.44
Model uncertainty
Medium
X-Ray Score
46/ 100 · High confidence · ahead of 35% of sector peers
Valuation59
Growth17
Profitability29
Financial health71
Dividends62
Five-year price chart navy: price · brown: 200-day average · blue band: fair value range
Executive summary
Albemarle is a specialty chemicals company centred on lithium, bromine and catalysts. Lithium compounds go to makers of batteries for electric vehicles and energy storage, bromine products serve fire-safety and electronics uses, and catalysts are supplied to oil refiners. The business is organised around energy storage, specialties and catalyst operations, and its customers are mostly industrial and manufacturing companies.
Earnings move with demand in end markets such as electric vehicles and with the volumes of chemicals supplied. Revenue is $5.9 billion over the last twelve months, but revenue growth over three years is -11.1% a year. The operating margin is 4.3%, and the business earns a profit of 2% on the capital invested in it. Albemarle carries net debt of 0.4 times EBITDA, and the dividend yield is 1.8%.
StocksXray gives Albemarle Corp an X-Ray Score of 46 out of 100 (high confidence), ahead of 35% of the S&P 500 stocks in its sector. Its strongest lens is financial health (71) and its weakest is growth (17).
Our fair value (the average of the valid models) is $97.12 (range $89.94 to $110.61). At $92.54 the stock trades 5% below that value, so the label is "Fair" with medium model uncertainty. Fair value is a range, not a price target.
XStocksXray
Albemarle Corp (ALB)
Valuation history multiples at each fiscal year-end price; the last column uses today's price and the last twelve months
FY2021
FY2022
FY2023
FY2024
FY2025
Now
Price
$220.27
$205.67
$138.22
$83.63
$140.26
$92.54
Market cap
$25.7B
$24.2B
$16.3B
$9.8B
$16.5B
$12.6B
P/E
207.8×
9.0×
10.3×
–
–
50.6×
EV / revenue
8.4×
3.6×
2.1×
2.3×
3.6×
2.2×
EV / EBITDA
26.4×
9.4×
29.1×
–
62.9×
14.7×
Price / free cash flow
–
37.2×
–
–
23.8×
9.4×
Free-cash-flow yield
−2.4%
2.7%
−5.1%
−10.1%
4.2%
10.6%
Price / book
4.6×
3.0×
1.7×
1.0×
1.7×
1.2×
Dividend yield
0.71%
0.77%
1.16%
1.93%
1.15%
1.76%
Fundamentals checklist ● 6 Good · ● 3 Average · ● 6 Bad · each check graded against the sector
Cash quality
Earnings backed by cash−9.9%Good
Free-cash-flow yield10.6%Good
Risk models
Altman Z score3.9×Good
Piotroski F-Score6 of 9Average
Growth
Free-cash-flow growth (3y)2.1%Average
Revenue growth (3y)−11.1%Bad
Growth consistency30%Bad
Balance sheet
Current ratio2.1×Good
Net debt / EBITDA0.4×Good
Interest coverno interest costGood
Valuation
Fair value vs price1.0×Average
EBIT / EV yield1.9%Bad
Profitability
Return on invested capital1.7%Bad
Operating margin4.3%Bad
Gross profitability8.8%Bad
XStocksXray
Albemarle Corp (ALB)
Financials US$ millions, from SEC filings; last column is the last twelve months
Income statement
FY21
FY22
FY23
FY24
FY25
LTM
Revenue
3,328
7,320
9,617
5,378
5,143
5,908
Gross profit
998
3,075
1,186
63
669
1,407
Operating income
798
2,470
252
-1,777
-367
252
Net income
124
2,690
1,573
-1,179
-511
224
Diluted EPS ($)
1.06
22.84
13.36
-11.20
-5.76
1.83
Free cash flow
-609
651
-828
-993
692
1,342
Gross margin
30.0%
42.0%
12.3%
1.2%
13.0%
23.8%
Operating margin
24.0%
33.7%
2.6%
−33.0%
−7.1%
4.3%
Net margin
3.7%
36.7%
16.4%
−21.9%
−9.9%
3.8%
Balance sheet
FY21
FY22
FY23
FY24
FY25
LTM
Total assets
10,974
15,457
18,271
16,610
16,374
15,905
Cash
439
1,499
890
1,192
1,618
1,632
Total debt
2,394
3,217
4,167
3,516
3,194
1,877
Equity
5,625
7,983
9,412
9,962
9,533
10,275
Dividend per share ($)
1.56
1.58
1.60
1.61
1.62
1.62
Revenue and net income US$ billions: navy revenue, teal net income
Every number comes from SEC filings, end-of-day prices and the StocksXray models described on the methodology page. The X-Ray Score ranks each metric against the company's own sector. Fair value is the average of up to 15 valuation models, most of them anchored to the company's own multiples, so it stays near the price and should be read as a range, not a point. Analyst ratings, price targets and earnings-call summaries are not part of this report. Educational research, not financial advice; read the disclaimer.
